There has been a remarkable explosion of knowledge into the molecular defects that underlie
the acute and chronic leukemias, leading to the introduction of targeted therapies that can …

The importance of the p53 protein in the cellular response to DNA damage is well known, but
its function during steady-state hematopoiesis has not been established. We have defined …

… In the version of this article initially published, the affiliation for Stephen D Nimer was
incorrect. Dr. Nimer is affiliated with the Division of Hematologic Oncology, Memorial Sloan-…

The chromosomal translocations found in acute myelogenous leukemia (AML) generate
oncogenic fusion transcription factors with aberrant transcriptional regulatory properties. …

BACKGROUND Aberrant DNA methylation, which results in leukemogenesis, is frequent in
patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic …

The myelodysplastic syndromes (MDSs) are heterogeneous with respect to clinical characteristics,
pathologic features, and cytogenetic abnormalities. This heterogeneity is a challenge …

Somatic loss-of-function mutations in the ten-eleven translocation 2 (TET2) gene occur in a
significant proportion of patients with myeloid malignancies. Although there are extensive …

Standardized criteria for assessing response are essential to ensure comparability among
clinical trials for patients with myelodysplastic syndromes (MDS). An international working …

Leukemic cells from 30% of patients with acute myeloid leukemia (AML) have an activating
mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a target for drug …

Recurrent somatic ASXL1 mutations occur in patients with myelodysplastic syndrome,
myeloproliferative neoplasms, and acute myeloid leukemia, and are associated with adverse …